SlideShare a Scribd company logo
1 of 90
3/10/2023 IV BOLUS 1
Pharmacokinetics
IV bolus, Multiple and Infusion
3/10/2023 IV BOLUS 2
Pharmacokinetics of IV bolus
One compartment open model
3/10/2023 IV BOLUS 3
Session objectives
• Determine p’k parameters
• Interpret the parameters
Assumptions
One compartment
A. Rapid Mixing
– drug is mixed instantaneously in
blood or plasma
B. Linear Model (dose-independent)
- First Order Kinetics
• Cp versus Time
3/10/2023 4
3/10/2023 IV BOLUS 5
Plasma Data
• Differential Equation
Developing Equation
• From rate vs Cp
3/10/2023 IV BOLUS 6
Plasma data…
Integrated equation
• Cp Vs time
CP= Cp
Oe-Kt
log Cp= logCp
O - kt/2.3
• DB Vs time
DB = DB
0e–kt
log DB = logDB
0 + - kt/2.3
where
• CP → plasma conc. at time t
• Cp
O → conc. at t=0
• DB → amount drug in the body at time t
• DB
0 → amount at t= 0
3/10/2023 7
Pharmacokinetic Parameters
1. Elimination rate constant, K
– fraction of drug removed per unit of
time
– Overall elimination rate constant
– Terminal elimination rate constant
K from
equation and slope
K from
• Slope of the semilog plot
• 1st order Half life, t1/2
t1/2 = 0.693/k
Parameters…
2. Amount of drug in the body, DB
DB = Cp VD
– Where VD relates [drug] in plasma (Cp) and the
amount of drug in the body (DB)
3. Apparent Volume of distribution, Vd
• VD = the volume in which the extent of drug distributed in the body
• VD for a given drug is constant
VD = DB
0/Cp
0 = dose/Cp
0
3/10/2023 IV BOLUS 8
Plasma data…
Apparent Volume of distribution...
3/10/2023 IV BOLUS 9
20
10
5
1
100mg injected at t=0
VD=100mg = 10L
10mg/L
VD= amount of drug injected
plasma concentration at t=o
Cp0
time
3/10/2023 IV BOLUS 10
Parameters…
4. Clearance, CL
• is a measure of drug elimination from the body
– Fixed volume of fluid (containing the drug) cleared of
drug per unit of time(volume/time, L/hr)
• Cl = elimination rate/CP = K Cp VD/Cp = K VD
5. Half life, t1/2
t1/2 = 0.693/K
Practical examples
1. A 70-kg volunteer is given an iv dose of an antibiotic, and
serum drug conc. were determined at 2 hours and 10
hours after administration. The drug conc. were 100µg/ml
and 10 µg/mL, respectively. What is the biologic half-life
for this drug?
2. If the amount of drug in the body declines from 100% of
the dose (IV bolus injection) to 25% of the dose in 8 hours,
what is the elimination half-life for this drug? (Assume first-
order kinetics.)
3/10/2023 IV BOLUS 11
3. A new drug was given in a single iv dose of 200 mg to an
80-kg adult male patient. After 6 hrs, the plasma drug conc.
of drug was 1.5 mg/100 mL of plasma. Assuming that the
apparent VD is 10% of body weight, compute the total
amount of drug in the body fluids after 6 hours. What is the
half-life of this drug?
4. A drug has an elimination t 1/2 of 6 hours. If a single 200-
mg dose is given to an adult male patient (68 kg) by IV
bolus, what percent of the dose is lost in 24hrs?
3/10/2023 IV BOLUS 12
3/10/2023 IV Multiple dose 13
Multiple IV bolus dosing
One compartment model
Objectives
• Discuss drug accumulation after repeated
dose administration
• Explain loading dose, maintenance dose, and
dosing interval
• Calculate appropriate multiple dose regimen
– to achieve desired Cpmin/Cpmax values
3/10/2023 IV Multiple dose 14
3/10/2023 IV Multiple dose 15
1. Introduction
• Most drugs are given as MDR
–MDR → prolonged therapeutic activity
• In designing a MDR,
–the target Cp must be related to the therapeutic response
–CP must be maintained within the TW
–p’k parameters are first obtained from single-dose studies
• Two main parameters - adjusted in MDR
1. Dose (Do)
2. Dosing interval (T)
3/10/2023 IV Multiple dose 16
1. Introduction…
• Superimposition is assumed
►early doses don’t affect the p’k of subsequent doses
►CP after the 2nd , 3rd or nth dose will overlay/superimpose
the CP attained after the (n–1)th dose
►Allows prediction of CP after multiple doses from a dose
Accumulation
• Subsequent doses given before drug from
previous dose(s) eliminated
Accumulation...
• Example: Rx: 100 mg dose qid (4mg/ml every 6h)
- (Literature data t1/2 = 6 hr and V = 25 L)
3/10/2023 IV Multiple dose 17
2. Accumulation...
• As a table
3/10/2023 IV Multiple dose 18
Start End Cp lost
4 --> 2 mg/L 2 mg/L
6 --> 3 mg/L 3 mg/L
7 --> 3.5 mg/L 3.5 mg/L
7.5 --> 3.75mg/L 3.75mg/L
... --> ... ...
8 --> 4mg/L 4mg/L
Drug accumulation...
Development of a General Equation
• At start of the first dose
Cp1= Cp1
0
• At the end of the first dosing interval, 
Cp1
= Cp1
0*e-k*
• At the start of the second interval
Cp2
0 = Cp1
0 + Cp1
= Cp1
0 + Cp1
0*e-k*
• At the end of the 2nd dosing interval, 
Cp2
= Cp1
0*e-k* +Cp1
0*(e-k*)2
• At the start of the 3rd interval
Cp3
= Cp1
0 + Cp1
0*e-k* +Cp1
0*(e-k*)2
3/10/2023 IV Multiple dose 19
Drug accumulation
Geometric Series
– Start of Interval, n
• Cpn
0 = Cp1
0 + Cp1
0 • R + Cp1
0 •R2 +...+ Cp1
0 •Rn-1
– End of Interval, n
» Cpn
T = Cp1
0 • R + Cp1
0 •R2 + Cp1
0 • R 3+ ...+ Cp1
0 •Rn
Sum of Geometric Series
At Start of Interval n (Cmax)
– Cpn
0 = Cp1
0[(1-Rn)/(1-R)] = D/VD[(1-e-nkT)/(1-e-kT)]
– At the End of Interval n (Cmin)
– Cpn
T = Cp1
0[(1-Rn)/(1-R)].R = D/VD[(1-e-nkT)/(1-e-kT)]. e-kT
3/10/2023 IV Multiple dose 20
3/10/2023 IV Multiple dose 21
Steady state/plateau
• Peak or max. conc. at steady state
Cmax,ss = Cp
o
* 1 = Do x 1
(1-e-k) Vd (1-e-k)
• Minimum or trough conc. at steady state
Cmin,ss = Cp
o
* e-k = Do x e-k
(1-e-k) Vd (1-e-k)
• Cmax,ss & Cmax,ss must be with in the TW
• 4 to 5 t1/2 to reach steady state
Drug accumulation
• Example
– Rx: 100 mg q6h; Assume the drug has t1/2 = 4 hr;
k=0.17h-1; V = 10L; R = e-0.17x6 = 0.35
• Question: What are Cmax and Cmin
– Cmax = Cp1
0 /(1-R) = Dose/v.(1-R)= 100/10.(1-0.35)=15.5mg/L
and
– CpT
∞ = Cmin=Dose.R/v.(1-R)=15.5mg/L x 0.35=5mg/L
3/10/2023 IV Multiple dose 22
3/10/2023 IV Multiple dose 23
Loading and maintenance doses
• Loading dose/priming
–The required Cp is quickly achieved
–DL = DM/(1-e-k)
 DL→ loading dose
 Dm→ maintenance dose
• Example Approach to Cmax
– Loading Dose = Cmax •V = 15.5 x 10 = 155mg
– Dosing Regimen: 155 mg IV loading dose
followed by 100 mg q6h
Loading and maintenance doses
• E.g., Rx: a physician wants to achieve plasma drug level of
Cmax=35 mg/L; Cmin=10mg/L after adm of an antibiotics as
MRD; (assume the Vd and k of drug are 25 L; and k=
0.15h-1, respectively).
– Question: Calculate Dosage Regimen
• Cmax/Cmin = 1/R
• R=10/35 = 0.2857= e-k,
• =8.35
– Using a dosing interval of 8h, R = e-k= e-8´0.15 = 0.3012
– Cmax = Do
V• (1-R)
– Dose = Cmax •V• (1-R) = 35 ´ 25 ´ (1- 0.3012) = 611 mg
3/10/2023 IV Multiple dose 24
Loading and maintenance doses
• The Dosing Regimen
– Loading Dose = Cmax • V = 35 x 25 = 875 mg
– Loading Dose: 875
– Maintenance Dose: 600 mg q8h
– Rx = 600mg TID, first adm a loading dose of
875mg
3/10/2023 IV Multiple dose 25
Average steady state blood levels
• Where
– Do = maintenance dose,
– F = fraction of dose absorbed,
–  = dosing interval
– t1/2 = half life
– 1.44 = reciprocal of 0.693
10 March 2023 MDR 26
Designing dosage regimen
10 March 2023 MDR 27
• Example 1: The elimination half-life of an
antibiotic is 3 hours and the apparent volume
of distribution is 20% of body weight. The
therapeutic window for this drug is from 2 to
10 µg/mL. Adverse toxicity is often observed
at drug concentrations above 15 µg/mL. The
drug will be given by multiple IV bolus
injections.
– a. Calculate the dose for an adult male patient
(68 years old, 82 kg) with normal renal function to
be given every 8 hours.
– b. Calculate the C ∞
av value.
Designing dosage regimen
10 March 2023 MDR 28
• A
• B
Designing dosage regimen
10 March 2023 MDR 29
• 2. Gentamicin has an average elimination
half-life of approximately 2 hours and an
apparent volume of distribution of 20% of
body weight. It is necessary to give
gentamicin, 1 mg/kg every 8 hours by
multiple IV injections, to a 50-kg woman
with normal renal function.
• Calculate (a) Cmax, and (b) C ∞
av.
Designing dosage regimen
10 March 2023 MDR 30
b.
Designing dosage regimen
10 March 2023 MDR 31
• Example 3: A patient receives 1000 mg every 6 hours
by repetitive IV injection of an antibiotic with an
elimination half-life of 3 hours. Assume the drug is
distributed according to a one-compartment model
and the volume of distribution is 20 L.
– Find the average amount of drug in the body.
Designing dosage regimen
10 March 2023 MDR 32
• Example 4. Patient C.S. is a 35-year-old
male weighing 76.6 kg. The patient is to
be given multiple IV bolus injections of an
antibiotic every 6 hrs. The effective conc.
of this drug is 15 µg/mL. After the patient
is given a single IV dose, the elimination
half-life for the drug is determined to be
3.0 hr and the VD is 196 mL/kg. Determine
a multiple IV dose regimen for this drug.
Designing dosage regimen
10 March 2023 MDR 33
IV INFUSION
ONE COMPARTMENT OPEN MODEL
3/10/2023 IV INFUSION 34
3/10/2023 IV INFUSION 35
Introduction
• Given slowly at a constant or
zero-order rate
• maintains an effective constant
plasma [drug]
– For drugs with a narrow TW
• allows precise control of plasma
[drug] to fit the individual needs
of the patient
• [Drug] is constant after a plateau
or steady-state
3/10/2023 IV INFUSION 36
CP - t relationship
At steady state:
• Rate at which the drug is leaving the body is equal to
the rate entering the body
• Infusion rate = elimination rate
• Rate of drug input = rate of drug output
• zero-order input and first-order output
• No net change in the Cp
dCp/dt = 0
3/10/2023 IV INFUSION 37
CP - t relationship….
• Change in the amount of drug in the body at any time =
– rate of input minus the rate of output
– (dDB/dt) = R - kDB …………1
R = infusion rate→ Dose/duration of infusion
DB = amount of drug in the body
K = 1st order elimination rate constant
• Integration above eq. and substitution of DB =C pVD gives
– Cp = R (1-e-kt)………………2
kVD
3/10/2023 IV INFUSION 38
Steady state Concentration (CSS)
• no net change in the amount of
drug in the body
Cp = (R/kVD)(1-e-kt)
• Theoretical Css is at t = ∞
• At t = ∞, e–kt approaches zero
Css= R/kVD = R/Cl
• CSS depends on R, k & VD
3/10/2023 IV INFUSION 39
Time to reach CSS
• Drug elimination is exponential (1st order)
– CP becomes asymptotic to the theoretical CSS
• Mathematically, the time to reach true steady-state drug
concentration, CSS, would take an infinite time
• The time for the CP to reach more than 95% of the CSS is
often taken as time for CSS
• About 4 to 5 t1/2
• = Time to reach desired therapeutic conc.
3/10/2023 IV INFUSION 40
Time to reach CSS……
Number of t 1/2 to reach a fraction of C SS
Percent of CSS reached Number of t1/2
90 3.32
95 4.32
99 6.65
3/10/2023 IV INFUSION 41
Time to reach CSS……
Example: no of t1/2 to reach 99% CSS
• Css= R/kVD
Cp = (R/kVD)(1-e-kt)
0.99 Css = Css (1-e-kt)
0.01 = e-kt
t99%SS= ln(0.01)/-k = 4.61/k = (4.61/0.693) t1/2= 6.65t1/2
• not dependent on the rate of infusion (an increase
infusion rate will not shorten the time to reach steady
state
• Depends on the elimination rate constant or t1/2
3/10/2023 IV INFUSION 42
Cp after infusion period
• If infusion stops at steady state or before steady, CP
declines according to first-order kinetics
• Stopped after steady state
Ct =Csse-kt
t → time after the infusion
• Similar to IV bolus, Co= Css
3/10/2023 IV INFUSION 43
Loading Dose (DL) Plus IV Infusion
• initial bolus dose used to obtain desired conc. as rapidly as
possible
– [drug] after an IV bolus dose C1 = Co. e-kt =(DL/VD)e-kt
– [drug] by infusion, C2 = (R/VDK) (1-e-kt)
• If DL & infusion is started at the same, Cp at t hours = C1 + C2
– Cp =(DL/VD) e-kt + (R/VD K) (1-e-kt)
– Cp = (DL/VD) e-kt + (R/VD K - R/VD K e-kt)
– Cp = R/VD K + (DL/VDe-kt - R/VD K e-kt)
• Let DL equal the amount of drug at SS,
DL = Css VD = R/K
DL Plus IV Infusion…
• Cp= R/VD K + (DL/VDe-kt - R/VD K e-kt)
• Substituting D L = R/k in above eq. makes the
expression in parentheses cancel out.
• Equation, therefore, is the same expression for
CSS or steady-state plasma concentration:
• Cp= R/VD K
• Css = R/VD K
3/10/2023 IV INFUSION 44
Examples
1. A physician wants to administer an anesthetic agent at a
rate of 2 mg/hr by IV infusion. The elimination rate
constant is 0.1 hr– 1, and the volume of distribution is 10 L.
What loading dose should be recommended if the doctor
wants the drug level to reach 2µg/mL immediately?
2. What is the concentration of a drug 6 hours after
administration of a loading dose of 10 mg and
simultaneous infusion at 2 mg/hr (the drug has a t 1/2 of 3
hr and a volume of distribution of 10 L)?
3/10/2023 IV INFUSION 45
3. . A female patient (35 years old, 65 kg) with normal renal function is to be given a
drug by IV infusion. According to the literature, the elimination half-life of this drug is
7 hours and the apparent V D is 23.1% of body weight. The pharmacokinetics of this
drug assumes a first-order process. The desired steady-state plasma level for this
antibiotic is 10 µg/mL.
• a. Assuming no loading dose, how long after the start of the IV infusion would it
take to reach 95% of the C SS?
• b. What is the proper loading dose for this antibiotic?
• c. What is the proper infusion rate for this drug?
• d. What is the total body clearance?
• e. If the total body clearance declined 50% due to partial renal failure, what new
infusion rate would you recommend to maintain the desired steady-state plasma
level of 10 µg/mL?
•
3/10/2023 IV BOLUS 46
3/10/2023 IV BOLUS 47
3/10/2023 p'k of extravascular dose 48
Pharmacokinetics of
extravascular dose
One compartment model
1. Introduction
Extravascular
• Not IV
• Involve an Absorption Step
including Oral, IM, SC, etc.
• Absorption Defined by
Rate and Extent
3/10/2023 p'k of extravascular dose 49
3/10/2023 p'k of extravascular dose 50
Introduction...
Oral route (oral doses)- Most commonly used route of admn.
• The rate of change in the amount of drug in the body, dDB/dt,
is the function of absorption and elimination rate.
• dDB/dt = dDGI/dt - dDE/dt
3/10/2023 p'k of extravascular dose 51
EV single dose equation
A. zero-order absorption
Cp = ko/(kVD)(1-e-kt)
B. 1st- order absorption
CP = FKaDo[e-kt - e-kat]
VD(Ka-k)
F
Dose Dose and DF parameters
Ka
Kel Drug and Patient parameters
V
3/10/2023 p'k of extravascular dose 52
Pharmacokinetic Parameters
1. tmax ,Time for maximum CP
• tmax = 1 ln Ka
Ka-K K
• independent of Do
• depend on ka and k
• Cmax is CP at tmax
K
Ka
K)
(Ka
.
t log
303
2
max 

3/10/2023 p'k of extravascular dose 53
2. determination of K
• Determined from the elimination phase of the Cp–time curve
CP = FKaDo[e-kt - e-kat]
VD(Ka-k)
• Assuming k a >> k in above Equation, the value for the
second exponential will become insignificantly small with
time (ie, e –k
a
t ≈ 0)
CP = FKaDo e-kt
VD(Ka-k)
CP = Ae-kt; A = fDKa/[VD(Ka-K)]
determination of K...
• CP = Ae-kt;
• This equation represents
first-order drug elimination,
• Plot logCp vs t
– slope = -k/2.3
– Intercept A
– Similar to IV bolus dose
3/10/2023 p'k of extravascular dose 54
3/10/2023 p'k of extravascular dose 55
3. Determination of Ka- Method of residuals
• Back Extrapolate the
elimination phase curve to t=0
– Curve AC is obtained
• Take ≥3 points on the upper
part of AC
– eg, x'1, x'2, x'3, ...
• Drop vertically to obtain
corresponding points on the
curve
– eg, x1, x2, x3, . . .
3/10/2023 p'k of extravascular dose 56
Ka-Method of residuals…..
• Plot the values of the d/ces at
the corresponding time points
– x'1-x1, x'2-x2, x'3-x3, ...
• A straight line will be obtained
slope =-ka/2.3
• Equation of the residual line
C’ = [fDKa/(VD(ka-K))]e-kat
C’ = x‘i-xi
3/10/2023 p'k of extravascular dose 57
4. Lag time-Method of residuals
• Time b/n administration and start of absorption
– Enteric coating tablets
– Gastric emptying
– Dissolution of capsule shell
The lag time t0 is subtracted from each time point
CP = FKaDo [e-k(t-to) - e-ka(t-to)]
VD(Ka-k)
5. Elimination half life
t1/2= 0.693/k
58
Effect of ka on Cmax, tmax, & AUC
• Increasing the
absorption rate
constant (Ka) results
in:
– Shorter tmax
– Higher Cmax
– Unchanged AUC
Changing Ka ( K unchanged)
59
Effect of K on tmax, Cmax, and
AUC
• Increasing the
elimination rate
constant (K) results
in:
– Shorter tmax
– Lower Cmax
– Lower AUC
Changing K ( Ka unchanged)
60
Effect F on tmax, Cmax, and AUC
0
50
100
150
200
250
300
0 20 40 60 80 100
time
Concentration
F = 1
F = 0.5
F = 0.25
 Increasing the bioavailability
results in:
 Unchanged tmax
 Higher Cmax
 Higher AUC
Example
A single oral dose (600 mg) of an antibiotic (90%
bioavailable) was given to an adult male patient (43 years,
72 kg). From the literature, the drug has ka = 1.0 hr-1, kel =
0.15 hr-1, and V = 30 liter.
calculate t max, C max, and t 1/2 for the drug in this patient..
3/10/2023 p'k of extravascular dose 61
3/10/2023 p'k of extravascular dose 62
MDR-extravascular
Multiple-Oral-Dose Regimen
• Cp at any time during an oral or EV MDR, assuming a
one-compartment model and constant doses and dose
interval, can be determined as follows:
– where
• n = number of doses,
• T= dosage interval,
• F = fraction of dose absorbed, and
• t = time after administration of n doses
3/10/2023 p'k of extravascular dose 63
3/10/2023 p'k of extravascular dose 64
Cp-time
3/10/2023 p'k of extravascular dose 65
C∞
max, C∞
min, C∞
av
tp –time for peak conc. at steady state
• C∞
av = FDo/VdK
3/10/2023 p'k of extravascular dose 66
Loading dose, DL
• To reduce the onset time of the
the time it takes to achieve the MEC
• DL/DM = 1/(1-e-kaT)(1-e-kT)
• Practically, for most drugs Ka>>>K
• DL/DM = 1/(1-e-kT)
DL = DM/(1-e-kT)
Example
• An adult male patient (46 yrs old, 81 kg) was given orally
250 mg of TTC HCl TID for 2 weeks. From the literature,
TTC is about 75% bioavailable and has Vd of 1.5 L/kg. k
is about 0.07 hr– 1 & Ka is 0.9 hr– 1.
From this information, calculate
(a) plasma drug concentration C p at 4 hours after the 7th
dose, Here, n=7, t=4, Ꞇ=8
3/10/2023 p'k of extravascular dose 67
(b) maximum plasma drug concentration at
steady-state C ∞
max,
3/10/2023 p'k of extravascular dose 68
(c) minimum plasma drug concentration at steady-state C ∞
min, and
(d) average plasma drug concentration at steady-state C ∞
av.
3/10/2023 p'k of extravascular dose 69
10 March 2023 MDR 70
• Example 2. A physician wants to give theophylline to a
young male asthmatic patient (age 29, 80 kg). According
to the literature, the drug has k of 5 hrs & VD equal to 50%
of body weight. The plasma level of theophylline required
to provide adequate airway ventilation is approximately 10
µg/mL.
– a. The physician wants the patient to take medication
every 6 hours around the clock. What dose of
theophylline would you recommend (assume
theophylline is 100% bioavailable)?
– b. If you were to find that theophylline is available to
you only in 225-mg capsules, what dosage regimen
would you recommend?
10 March 2023 MDR 71
72
Design of Dosage Regimen
Dosage regimen
10 March 2023 73
Dosage Regimen – the manner in which the
drug is taken.
– Some are taken as single dose, however, most
drugs are taken on a repetitive bases
– For successful therapy, design of an optimal
multiple dosage regimen (MDR) is necessary.
• MDR:- is the manner in which the drug is
administered in suitable doses by suitable
route, with sufficient frequency that insures
maintenance of Cp within TI for entire period of
therapy.
Approaches to Design of Dosage
Regimen
74
The various approaches employed in
designing a dosage regimen are –
1. Empirical Dosage Regimen
2. Population Averages Dosage Regimen
(a) Fixed model
(b) Adaptive model
3. Individualized Dosage Regimen
» based on the phks of drug in the individual
patient.
1. Empirical Dosage Regimen
75
Designed by the physician based on
– Empirical clinical data,
– Personal experience and
– Clinical observations.
• In many cases, the physician selects a DR for
the patient without using any ph’k variables.
• This approach is, however, not very accurate.
2. Population Averages Dosage
Regimens
76
DR based on Population Averages–
• Is the most often used approach.
• is based on one of the two models
a) The fixed model
– Based on population average ph’k parameters.
– This parameters are used directly to calculate a DR for
the patient.
• Ph’k parameters such as ka, F, VD, & k, are assumed to remain
constant.
• Drug is assumed to follow the phk of a one-compartment
model.
• When a MDR is designed, multiple-dosage equations based on
the principle of superposition are used to evaluate the dose.
b) The adaptive model
77
The adaptive model is Based on
 Population average ph’k parameters of the drug as well as
 Patient variables such as weight, age, sex, body surface
area and known patient pathophysiology such as renal
disease.
• Calculation of the DR takes into consideration
– any changing pathophysiology of the patient &
attempts to adapt or modify the DR according to
the needs of the patient.
Fixed model: Designing MDR
78
Irrespective of the route of adm. & complexity of ph’k
equations, the two major parameters that can be
adjusted in developing a DR are
1. The dose size
2. The dosing frequency
Both parameters govern the amount of drug in the
body at any given time.
Fixed Model: Dose size
79
The magnitude of both therapeutic and toxic
responses depends upon dose size.
• Greater the dose size, greater the fluctuations
between Css,max & Css,min during each dosing
interval & greater the chances of toxicity (Fig.
below).
• For drugs administered chronically, dose size
calculation is based on average Css & is computed
from equation:
Fixed Model: Dose size
80
Fig: influence of dose size on CpVs t after oral adm of a drug at fixed
intervals of time.
Fixed Model: Dose size
Determination of Dose: Examples
81
According to literature, the t1/2 of tobramycin was reported to be 2.15
hrs & the VD was reported to be 33.5% of body weight. What is the
dose for an 80-kg pt if Css level of 2.5 g/mL is desired? Assume that
the drug is given by IV bolus injection TID.
• Solution Assuming the drug is 100% BA as a result of IV injection,
• The dose should be 173 mg every 8 hours.
Fixed Model: Dosing
Frequency
82
• The dose interval (inverse of dosing
frequency) is calculated on the basis of
half-life of the drug.
• If the interval is increased and the dose is
unchanged, Cmax, Cmin and Cav decrease
but the ratio Cmax/Cmin increases.
• Opposite is observed when dosing interval
is reduced or dosing frequency increased.
– It also results in greater drug accumulation in
the body and toxicity (see Fig.).
Fixed Model: Dosing Frequency
83
Fig: influence of dosing frequency on CpVs t profile after
oral adm of a drug at fixed dose of a drug
Fixed Model: Dosing
Frequency
84
• A proper balance b/n both dose size
and dosing frequency is often desired
to attain steady-state conc. with minimum
fluctuations and to ensure therapeutic
efficacy & safety.
– The same cannot be obtained by giving larger
doses less frequently.
– However, administering smaller doses more
frequently results in smaller fluctuations
Fixed Model: Dosing
Frequency…
85
Generally speaking, every subsequent dose should
be administered at an interval equal to half-life of
the drug.
A rule of thumb is that –
• For drugs with wide TI such as penicillin,
– Larger doses may be administered at relatively longer
intervals (˃t1/2 of drug) without any toxicity problem
• For drugs with narrow TI such as digoxin,
– Small doses at frequent intervals (usually ˂ t1/2) is better
to obtain a profile with least fluctuations (similar to
constant rate infusion or controlled-release system).
Fixed Model: Dosing Frequency
Determination of Frequency
Example
86
• For example,
– Dm of digoxin is 0.25 mg/day & its t1/2 is 1.7 days.
– Dm of penicillin G is 250 mg QID, while its t1/2 is 0.75
hr.
– Penicillin is given at  = 8x t1/2 , whereas digoxin is
given at  = 0.59x t1/2 0.59.
– The toxic Cp of penicillin G is over 100x ˃ its effective
Cp,
– The toxic Cp of digoxin is only 1.5x ˃ its effective.
• Therefore,
– a drug with a large TI can be given in large doses and
at relatively long dosing intervals.
Fixed Model: Dosing Frequency
Determination of Frequency Example
87
The size of a drug dose is often related to the
frequency of drug administration.
• The more frequently a drug is administered, the
smaller the dose must be to obtain the same C∞
av.
• Thus, a dose of 250 mg every 3 hours could be
changed to 500 mg every 6 hours without affecting
the C∞
av of the drug.
– However, as dosing intervals , the size of the dose
required to maintain the C∞
av gets larger.
– When an excessively long dosing interval is chosen,
the large dose may result in peak plasma levels that
are above toxic drug conc, even though C∞
av will
remain the same.
Fixed Model: Determination of Both Dose
and Dosage Interval
88
• Both Do &  should be considered in the DR calculations.
• Ideally, the calculated DR should maintain the serum drug
conc between C∞
max and C∞
min.
• For IV MDR the ratio of C ∞
max/C ∞
min may be expressed by
• Which can be simplified to
Fixed Model: Determination of
Both Dose and Dosage Interval
89
Practice Problem
• The t1/2 of an antibiotic is 3 hrs with Vd of 20% of body Wt. The
usual therapeutic range for this antibiotic is between 5 &
15g/mL. Calculate a DR (multiple IV doses) that will just
maintain the serum drug conc b/n 5 & 15g/mL.
Solution
• From the above Equation, determine the maximum possible
dosage interval .
Take the natural logarithm (ln) on
both size of the equation
Fixed Model: Determination of
Both Dose and Dosage Interval
90
By calculation, the dose of this antibiotic should be 2 mg/kg every
4.76 hours to maintain the serum drug concentration between 5
and 15  g/mL.

More Related Content

What's hot

Two compartment open model sulekhappt.x.1
Two compartment open model sulekhappt.x.1Two compartment open model sulekhappt.x.1
Two compartment open model sulekhappt.x.1Sulekha Rohilla
 
Non compartmental pharmacokinetics & physiologic pharmacokinetic models by akt
Non compartmental pharmacokinetics & physiologic pharmacokinetic models by aktNon compartmental pharmacokinetics & physiologic pharmacokinetic models by akt
Non compartmental pharmacokinetics & physiologic pharmacokinetic models by aktDr Ajay Kumar Tiwari
 
Physiological pharmacokinetic models
Physiological pharmacokinetic modelsPhysiological pharmacokinetic models
Physiological pharmacokinetic modelsSanjay Yadav
 
Non linear Pharmacokinetics 2
Non linear Pharmacokinetics 2Non linear Pharmacokinetics 2
Non linear Pharmacokinetics 2Areej Abu Hanieh
 
Introduction to dosage regimen and Individualization of dosage regimen
Introduction to dosage regimen and Individualization of dosage regimenIntroduction to dosage regimen and Individualization of dosage regimen
Introduction to dosage regimen and Individualization of dosage regimenKLE College of pharmacy
 
METHOD OF RESIDUALS
METHOD OF RESIDUALSMETHOD OF RESIDUALS
METHOD OF RESIDUALSDivya Pushp
 
Methods of Assessing Bioavailability
Methods of Assessing BioavailabilityMethods of Assessing Bioavailability
Methods of Assessing BioavailabilityDibrugarh University
 
One compartment-open-model
One compartment-open-modelOne compartment-open-model
One compartment-open-modelRana Ahmed
 
Pharmacokinetics / Biopharmaceutics - Drug Elimination
Pharmacokinetics / Biopharmaceutics - Drug Elimination Pharmacokinetics / Biopharmaceutics - Drug Elimination
Pharmacokinetics / Biopharmaceutics - Drug Elimination Areej Abu Hanieh
 
Bioavailability and bioequivalence
Bioavailability and bioequivalenceBioavailability and bioequivalence
Bioavailability and bioequivalenceNaresh Gorantla
 
Pharmacokinetics / Biopharmaceutics - Multi compartment IV bolus
Pharmacokinetics / Biopharmaceutics - Multi compartment IV bolusPharmacokinetics / Biopharmaceutics - Multi compartment IV bolus
Pharmacokinetics / Biopharmaceutics - Multi compartment IV bolusAreej Abu Hanieh
 
Two compartment model iv bolus muju
Two compartment model iv bolus mujuTwo compartment model iv bolus muju
Two compartment model iv bolus mujuHirepravin
 
Non linear Pharmacokinetics
Non linear PharmacokineticsNon linear Pharmacokinetics
Non linear PharmacokineticsAreej Abu Hanieh
 
Methods to determine area under curve
Methods to determine area under curveMethods to determine area under curve
Methods to determine area under curveMd.Rakibul Islam
 
one compartment model ppt
one compartment model pptone compartment model ppt
one compartment model pptSheetal Jha
 

What's hot (20)

Bioavailability testing protocol
Bioavailability testing protocolBioavailability testing protocol
Bioavailability testing protocol
 
Two compartment open model sulekhappt.x.1
Two compartment open model sulekhappt.x.1Two compartment open model sulekhappt.x.1
Two compartment open model sulekhappt.x.1
 
Non compartmental pharmacokinetics & physiologic pharmacokinetic models by akt
Non compartmental pharmacokinetics & physiologic pharmacokinetic models by aktNon compartmental pharmacokinetics & physiologic pharmacokinetic models by akt
Non compartmental pharmacokinetics & physiologic pharmacokinetic models by akt
 
Physiological pharmacokinetic models
Physiological pharmacokinetic modelsPhysiological pharmacokinetic models
Physiological pharmacokinetic models
 
Non linear Pharmacokinetics 2
Non linear Pharmacokinetics 2Non linear Pharmacokinetics 2
Non linear Pharmacokinetics 2
 
Introduction to dosage regimen and Individualization of dosage regimen
Introduction to dosage regimen and Individualization of dosage regimenIntroduction to dosage regimen and Individualization of dosage regimen
Introduction to dosage regimen and Individualization of dosage regimen
 
Pharmacokinetic models
Pharmacokinetic  modelsPharmacokinetic  models
Pharmacokinetic models
 
METHOD OF RESIDUALS
METHOD OF RESIDUALSMETHOD OF RESIDUALS
METHOD OF RESIDUALS
 
Dosage regimen
Dosage regimenDosage regimen
Dosage regimen
 
Methods of Assessing Bioavailability
Methods of Assessing BioavailabilityMethods of Assessing Bioavailability
Methods of Assessing Bioavailability
 
One compartment-open-model
One compartment-open-modelOne compartment-open-model
One compartment-open-model
 
Pharmacokinetics / Biopharmaceutics - Drug Elimination
Pharmacokinetics / Biopharmaceutics - Drug Elimination Pharmacokinetics / Biopharmaceutics - Drug Elimination
Pharmacokinetics / Biopharmaceutics - Drug Elimination
 
Bioavailability and bioequivalence
Bioavailability and bioequivalenceBioavailability and bioequivalence
Bioavailability and bioequivalence
 
Pharmacokinetics / Biopharmaceutics - Multi compartment IV bolus
Pharmacokinetics / Biopharmaceutics - Multi compartment IV bolusPharmacokinetics / Biopharmaceutics - Multi compartment IV bolus
Pharmacokinetics / Biopharmaceutics - Multi compartment IV bolus
 
Two compartment model iv bolus muju
Two compartment model iv bolus mujuTwo compartment model iv bolus muju
Two compartment model iv bolus muju
 
Non linear Pharmacokinetics
Non linear PharmacokineticsNon linear Pharmacokinetics
Non linear Pharmacokinetics
 
Methods to determine area under curve
Methods to determine area under curveMethods to determine area under curve
Methods to determine area under curve
 
one compartment model ppt
one compartment model pptone compartment model ppt
one compartment model ppt
 
Calculations of Doses
Calculations of DosesCalculations of Doses
Calculations of Doses
 
Loading dose plus iv infusion
Loading dose plus iv infusionLoading dose plus iv infusion
Loading dose plus iv infusion
 

Similar to 2. Basic Phk-IV and EV.pptx

Calculate and Interpret Pharmacokinetic Parameters of a Given Drug
Calculate and Interpret Pharmacokinetic Parameters of a Given DrugCalculate and Interpret Pharmacokinetic Parameters of a Given Drug
Calculate and Interpret Pharmacokinetic Parameters of a Given DrugShivankan Kakkar
 
05_Multiple dosing IV bolus.ppt
05_Multiple dosing IV bolus.ppt05_Multiple dosing IV bolus.ppt
05_Multiple dosing IV bolus.pptNoorelhuda2
 
Aminoglycoside Pharmacokinetics/Pharmacodynamics
Aminoglycoside Pharmacokinetics/PharmacodynamicsAminoglycoside Pharmacokinetics/Pharmacodynamics
Aminoglycoside Pharmacokinetics/PharmacodynamicsYazan Kherallah
 
Pharmacokinetics / Biopharmaceutics - Multi dosage regimens
Pharmacokinetics / Biopharmaceutics - Multi dosage regimensPharmacokinetics / Biopharmaceutics - Multi dosage regimens
Pharmacokinetics / Biopharmaceutics - Multi dosage regimensAreej Abu Hanieh
 
Biopharmaceutics & Pharmacokinetics (Ultimate final note)
Biopharmaceutics & Pharmacokinetics (Ultimate final note)Biopharmaceutics & Pharmacokinetics (Ultimate final note)
Biopharmaceutics & Pharmacokinetics (Ultimate final note)MdNazmulIslamTanmoy
 
CO1_L10_ Introduction to Pharmacology and Therapeutics Part 3.pptx
CO1_L10_ Introduction to Pharmacology and Therapeutics  Part 3.pptxCO1_L10_ Introduction to Pharmacology and Therapeutics  Part 3.pptx
CO1_L10_ Introduction to Pharmacology and Therapeutics Part 3.pptxSamwel Samwel
 
Calculation of the plasma drug levels after a single dose IVinfusion..pptx
Calculation of the plasma drug levels after a single dose IVinfusion..pptxCalculation of the plasma drug levels after a single dose IVinfusion..pptx
Calculation of the plasma drug levels after a single dose IVinfusion..pptxSARADPAWAR1
 
B darpo so c december 4 2014 - kopia
B darpo so c december 4 2014 - kopiaB darpo so c december 4 2014 - kopia
B darpo so c december 4 2014 - kopiaSasha Latypova
 
IV-Bolus-and-Infusion.ppt
IV-Bolus-and-Infusion.pptIV-Bolus-and-Infusion.ppt
IV-Bolus-and-Infusion.pptNoorelhuda2
 
Biopharmaceutics: Multiple dosage regimens
Biopharmaceutics: Multiple dosage regimensBiopharmaceutics: Multiple dosage regimens
Biopharmaceutics: Multiple dosage regimensSonia Barua
 
Pharmacokinetics / Biopharmaceutics - drug absorption
Pharmacokinetics / Biopharmaceutics - drug absorptionPharmacokinetics / Biopharmaceutics - drug absorption
Pharmacokinetics / Biopharmaceutics - drug absorptionAreej Abu Hanieh
 
Concept of therapeutic drug monitoring .pdf
Concept of therapeutic drug monitoring .pdfConcept of therapeutic drug monitoring .pdf
Concept of therapeutic drug monitoring .pdfUVAS
 
BP 604T unit 3 notes.docx
BP 604T unit 3 notes.docxBP 604T unit 3 notes.docx
BP 604T unit 3 notes.docxAlka Maral
 
Pharacokinetics power point for pharmacy
Pharacokinetics power point  for pharmacyPharacokinetics power point  for pharmacy
Pharacokinetics power point for pharmacyemebetnigatu1
 
Application of pharmacokinetics
Application of pharmacokineticsApplication of pharmacokinetics
Application of pharmacokineticsChristy George
 
one compartment open model
one compartment open modelone compartment open model
one compartment open modelSUJITHA MARY
 

Similar to 2. Basic Phk-IV and EV.pptx (20)

Calculate and Interpret Pharmacokinetic Parameters of a Given Drug
Calculate and Interpret Pharmacokinetic Parameters of a Given DrugCalculate and Interpret Pharmacokinetic Parameters of a Given Drug
Calculate and Interpret Pharmacokinetic Parameters of a Given Drug
 
05_Multiple dosing IV bolus.ppt
05_Multiple dosing IV bolus.ppt05_Multiple dosing IV bolus.ppt
05_Multiple dosing IV bolus.ppt
 
multiple-dosage-regimen.pdf
multiple-dosage-regimen.pdfmultiple-dosage-regimen.pdf
multiple-dosage-regimen.pdf
 
Clinical pharmacokinetics
Clinical pharmacokineticsClinical pharmacokinetics
Clinical pharmacokinetics
 
Aminoglycoside Pharmacokinetics/Pharmacodynamics
Aminoglycoside Pharmacokinetics/PharmacodynamicsAminoglycoside Pharmacokinetics/Pharmacodynamics
Aminoglycoside Pharmacokinetics/Pharmacodynamics
 
Pharmacokinetics / Biopharmaceutics - Multi dosage regimens
Pharmacokinetics / Biopharmaceutics - Multi dosage regimensPharmacokinetics / Biopharmaceutics - Multi dosage regimens
Pharmacokinetics / Biopharmaceutics - Multi dosage regimens
 
Biopharmaceutics & Pharmacokinetics (Ultimate final note)
Biopharmaceutics & Pharmacokinetics (Ultimate final note)Biopharmaceutics & Pharmacokinetics (Ultimate final note)
Biopharmaceutics & Pharmacokinetics (Ultimate final note)
 
CO1_L10_ Introduction to Pharmacology and Therapeutics Part 3.pptx
CO1_L10_ Introduction to Pharmacology and Therapeutics  Part 3.pptxCO1_L10_ Introduction to Pharmacology and Therapeutics  Part 3.pptx
CO1_L10_ Introduction to Pharmacology and Therapeutics Part 3.pptx
 
Pharmacokinetic Models
Pharmacokinetic ModelsPharmacokinetic Models
Pharmacokinetic Models
 
Calculation of the plasma drug levels after a single dose IVinfusion..pptx
Calculation of the plasma drug levels after a single dose IVinfusion..pptxCalculation of the plasma drug levels after a single dose IVinfusion..pptx
Calculation of the plasma drug levels after a single dose IVinfusion..pptx
 
B darpo so c december 4 2014 - kopia
B darpo so c december 4 2014 - kopiaB darpo so c december 4 2014 - kopia
B darpo so c december 4 2014 - kopia
 
IV-Bolus-and-Infusion.ppt
IV-Bolus-and-Infusion.pptIV-Bolus-and-Infusion.ppt
IV-Bolus-and-Infusion.ppt
 
Leukemia case answer
Leukemia case answerLeukemia case answer
Leukemia case answer
 
Biopharmaceutics: Multiple dosage regimens
Biopharmaceutics: Multiple dosage regimensBiopharmaceutics: Multiple dosage regimens
Biopharmaceutics: Multiple dosage regimens
 
Pharmacokinetics / Biopharmaceutics - drug absorption
Pharmacokinetics / Biopharmaceutics - drug absorptionPharmacokinetics / Biopharmaceutics - drug absorption
Pharmacokinetics / Biopharmaceutics - drug absorption
 
Concept of therapeutic drug monitoring .pdf
Concept of therapeutic drug monitoring .pdfConcept of therapeutic drug monitoring .pdf
Concept of therapeutic drug monitoring .pdf
 
BP 604T unit 3 notes.docx
BP 604T unit 3 notes.docxBP 604T unit 3 notes.docx
BP 604T unit 3 notes.docx
 
Pharacokinetics power point for pharmacy
Pharacokinetics power point  for pharmacyPharacokinetics power point  for pharmacy
Pharacokinetics power point for pharmacy
 
Application of pharmacokinetics
Application of pharmacokineticsApplication of pharmacokinetics
Application of pharmacokinetics
 
one compartment open model
one compartment open modelone compartment open model
one compartment open model
 

More from jiregna5

3. Clinical Phk-Dosing in special Population & TDM.pptx
3. Clinical Phk-Dosing in special Population & TDM.pptx3. Clinical Phk-Dosing in special Population & TDM.pptx
3. Clinical Phk-Dosing in special Population & TDM.pptxjiregna5
 
CHAPTER 6&7.docx
CHAPTER 6&7.docxCHAPTER 6&7.docx
CHAPTER 6&7.docxjiregna5
 
Biological-lecture 2-2022-23.pdf
Biological-lecture 2-2022-23.pdfBiological-lecture 2-2022-23.pdf
Biological-lecture 2-2022-23.pdfjiregna5
 
1. Int-Phk-Rate- Model-ADME.pptx
1. Int-Phk-Rate- Model-ADME.pptx1. Int-Phk-Rate- Model-ADME.pptx
1. Int-Phk-Rate- Model-ADME.pptxjiregna5
 
GENE THERAPY AND GENE DELIVERY SYSTEMS GROUP 5.pptx
GENE THERAPY AND GENE DELIVERY SYSTEMS GROUP 5.pptxGENE THERAPY AND GENE DELIVERY SYSTEMS GROUP 5.pptx
GENE THERAPY AND GENE DELIVERY SYSTEMS GROUP 5.pptxjiregna5
 
Asthma.pptx
Asthma.pptxAsthma.pptx
Asthma.pptxjiregna5
 
barbiturates.pptx
barbiturates.pptxbarbiturates.pptx
barbiturates.pptxjiregna5
 
Osteoarthritis (OA)_071115 (1).pptx
Osteoarthritis (OA)_071115 (1).pptxOsteoarthritis (OA)_071115 (1).pptx
Osteoarthritis (OA)_071115 (1).pptxjiregna5
 
Gout and Hyperuricemia.pptx
Gout and Hyperuricemia.pptxGout and Hyperuricemia.pptx
Gout and Hyperuricemia.pptxjiregna5
 
Glaucoma group-2.pptx
Glaucoma group-2.pptxGlaucoma group-2.pptx
Glaucoma group-2.pptxjiregna5
 
pharm build z team and manage the conflict (1).pptx
pharm build z team and manage the conflict (1).pptxpharm build z team and manage the conflict (1).pptx
pharm build z team and manage the conflict (1).pptxjiregna5
 
Pharmacotherapy of Heart Failure.pptx
Pharmacotherapy of Heart Failure.pptxPharmacotherapy of Heart Failure.pptx
Pharmacotherapy of Heart Failure.pptxjiregna5
 
Clinical toxicology .pptx
Clinical toxicology .pptxClinical toxicology .pptx
Clinical toxicology .pptxjiregna5
 
3-Fluid & elect-A (1).pptx
3-Fluid & elect-A (1).pptx3-Fluid & elect-A (1).pptx
3-Fluid & elect-A (1).pptxjiregna5
 
4-DIKD-2022 (2).pptx
4-DIKD-2022 (2).pptx4-DIKD-2022 (2).pptx
4-DIKD-2022 (2).pptxjiregna5
 
Autacoids.pptx
Autacoids.pptxAutacoids.pptx
Autacoids.pptxjiregna5
 
2. PHC.pptx
2. PHC.pptx2. PHC.pptx
2. PHC.pptxjiregna5
 
hsmmm.pptx
hsmmm.pptxhsmmm.pptx
hsmmm.pptxjiregna5
 
Pharmacology of PUD.ppt
Pharmacology of PUD.pptPharmacology of PUD.ppt
Pharmacology of PUD.pptjiregna5
 
Autacoids.pptx
Autacoids.pptxAutacoids.pptx
Autacoids.pptxjiregna5
 

More from jiregna5 (20)

3. Clinical Phk-Dosing in special Population & TDM.pptx
3. Clinical Phk-Dosing in special Population & TDM.pptx3. Clinical Phk-Dosing in special Population & TDM.pptx
3. Clinical Phk-Dosing in special Population & TDM.pptx
 
CHAPTER 6&7.docx
CHAPTER 6&7.docxCHAPTER 6&7.docx
CHAPTER 6&7.docx
 
Biological-lecture 2-2022-23.pdf
Biological-lecture 2-2022-23.pdfBiological-lecture 2-2022-23.pdf
Biological-lecture 2-2022-23.pdf
 
1. Int-Phk-Rate- Model-ADME.pptx
1. Int-Phk-Rate- Model-ADME.pptx1. Int-Phk-Rate- Model-ADME.pptx
1. Int-Phk-Rate- Model-ADME.pptx
 
GENE THERAPY AND GENE DELIVERY SYSTEMS GROUP 5.pptx
GENE THERAPY AND GENE DELIVERY SYSTEMS GROUP 5.pptxGENE THERAPY AND GENE DELIVERY SYSTEMS GROUP 5.pptx
GENE THERAPY AND GENE DELIVERY SYSTEMS GROUP 5.pptx
 
Asthma.pptx
Asthma.pptxAsthma.pptx
Asthma.pptx
 
barbiturates.pptx
barbiturates.pptxbarbiturates.pptx
barbiturates.pptx
 
Osteoarthritis (OA)_071115 (1).pptx
Osteoarthritis (OA)_071115 (1).pptxOsteoarthritis (OA)_071115 (1).pptx
Osteoarthritis (OA)_071115 (1).pptx
 
Gout and Hyperuricemia.pptx
Gout and Hyperuricemia.pptxGout and Hyperuricemia.pptx
Gout and Hyperuricemia.pptx
 
Glaucoma group-2.pptx
Glaucoma group-2.pptxGlaucoma group-2.pptx
Glaucoma group-2.pptx
 
pharm build z team and manage the conflict (1).pptx
pharm build z team and manage the conflict (1).pptxpharm build z team and manage the conflict (1).pptx
pharm build z team and manage the conflict (1).pptx
 
Pharmacotherapy of Heart Failure.pptx
Pharmacotherapy of Heart Failure.pptxPharmacotherapy of Heart Failure.pptx
Pharmacotherapy of Heart Failure.pptx
 
Clinical toxicology .pptx
Clinical toxicology .pptxClinical toxicology .pptx
Clinical toxicology .pptx
 
3-Fluid & elect-A (1).pptx
3-Fluid & elect-A (1).pptx3-Fluid & elect-A (1).pptx
3-Fluid & elect-A (1).pptx
 
4-DIKD-2022 (2).pptx
4-DIKD-2022 (2).pptx4-DIKD-2022 (2).pptx
4-DIKD-2022 (2).pptx
 
Autacoids.pptx
Autacoids.pptxAutacoids.pptx
Autacoids.pptx
 
2. PHC.pptx
2. PHC.pptx2. PHC.pptx
2. PHC.pptx
 
hsmmm.pptx
hsmmm.pptxhsmmm.pptx
hsmmm.pptx
 
Pharmacology of PUD.ppt
Pharmacology of PUD.pptPharmacology of PUD.ppt
Pharmacology of PUD.ppt
 
Autacoids.pptx
Autacoids.pptxAutacoids.pptx
Autacoids.pptx
 

Recently uploaded

Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfSumit Tiwari
 
Interactive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationInteractive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationnomboosow
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxSayali Powar
 
MARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized GroupMARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized GroupJonathanParaisoCruz
 
Capitol Tech U Doctoral Presentation - April 2024.pptx
Capitol Tech U Doctoral Presentation - April 2024.pptxCapitol Tech U Doctoral Presentation - April 2024.pptx
Capitol Tech U Doctoral Presentation - April 2024.pptxCapitolTechU
 
CELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxCELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxJiesonDelaCerna
 
Biting mechanism of poisonous snakes.pdf
Biting mechanism of poisonous snakes.pdfBiting mechanism of poisonous snakes.pdf
Biting mechanism of poisonous snakes.pdfadityarao40181
 
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...M56BOOKSTORE PRODUCT/SERVICE
 
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Celine George
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...Marc Dusseiller Dusjagr
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceSamikshaHamane
 
Earth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatEarth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatYousafMalik24
 
Final demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxFinal demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxAvyJaneVismanos
 
DATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersDATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersSabitha Banu
 
Pharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfPharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfMahmoud M. Sallam
 
call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️9953056974 Low Rate Call Girls In Saket, Delhi NCR
 
Meghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentMeghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentInMediaRes1
 
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxEPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxRaymartEstabillo3
 
How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17Celine George
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)eniolaolutunde
 

Recently uploaded (20)

Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
 
Interactive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationInteractive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communication
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
 
MARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized GroupMARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized Group
 
Capitol Tech U Doctoral Presentation - April 2024.pptx
Capitol Tech U Doctoral Presentation - April 2024.pptxCapitol Tech U Doctoral Presentation - April 2024.pptx
Capitol Tech U Doctoral Presentation - April 2024.pptx
 
CELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxCELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptx
 
Biting mechanism of poisonous snakes.pdf
Biting mechanism of poisonous snakes.pdfBiting mechanism of poisonous snakes.pdf
Biting mechanism of poisonous snakes.pdf
 
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
 
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in Pharmacovigilance
 
Earth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatEarth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice great
 
Final demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxFinal demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptx
 
DATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersDATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginners
 
Pharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfPharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdf
 
call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
 
Meghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentMeghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media Component
 
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxEPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
 
How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)
 

2. Basic Phk-IV and EV.pptx

  • 1. 3/10/2023 IV BOLUS 1 Pharmacokinetics IV bolus, Multiple and Infusion
  • 2. 3/10/2023 IV BOLUS 2 Pharmacokinetics of IV bolus One compartment open model
  • 3. 3/10/2023 IV BOLUS 3 Session objectives • Determine p’k parameters • Interpret the parameters
  • 4. Assumptions One compartment A. Rapid Mixing – drug is mixed instantaneously in blood or plasma B. Linear Model (dose-independent) - First Order Kinetics • Cp versus Time 3/10/2023 4
  • 5. 3/10/2023 IV BOLUS 5 Plasma Data • Differential Equation Developing Equation • From rate vs Cp
  • 6. 3/10/2023 IV BOLUS 6 Plasma data… Integrated equation • Cp Vs time CP= Cp Oe-Kt log Cp= logCp O - kt/2.3 • DB Vs time DB = DB 0e–kt log DB = logDB 0 + - kt/2.3 where • CP → plasma conc. at time t • Cp O → conc. at t=0 • DB → amount drug in the body at time t • DB 0 → amount at t= 0
  • 7. 3/10/2023 7 Pharmacokinetic Parameters 1. Elimination rate constant, K – fraction of drug removed per unit of time – Overall elimination rate constant – Terminal elimination rate constant K from equation and slope K from • Slope of the semilog plot • 1st order Half life, t1/2 t1/2 = 0.693/k
  • 8. Parameters… 2. Amount of drug in the body, DB DB = Cp VD – Where VD relates [drug] in plasma (Cp) and the amount of drug in the body (DB) 3. Apparent Volume of distribution, Vd • VD = the volume in which the extent of drug distributed in the body • VD for a given drug is constant VD = DB 0/Cp 0 = dose/Cp 0 3/10/2023 IV BOLUS 8
  • 9. Plasma data… Apparent Volume of distribution... 3/10/2023 IV BOLUS 9 20 10 5 1 100mg injected at t=0 VD=100mg = 10L 10mg/L VD= amount of drug injected plasma concentration at t=o Cp0 time
  • 10. 3/10/2023 IV BOLUS 10 Parameters… 4. Clearance, CL • is a measure of drug elimination from the body – Fixed volume of fluid (containing the drug) cleared of drug per unit of time(volume/time, L/hr) • Cl = elimination rate/CP = K Cp VD/Cp = K VD 5. Half life, t1/2 t1/2 = 0.693/K
  • 11. Practical examples 1. A 70-kg volunteer is given an iv dose of an antibiotic, and serum drug conc. were determined at 2 hours and 10 hours after administration. The drug conc. were 100µg/ml and 10 µg/mL, respectively. What is the biologic half-life for this drug? 2. If the amount of drug in the body declines from 100% of the dose (IV bolus injection) to 25% of the dose in 8 hours, what is the elimination half-life for this drug? (Assume first- order kinetics.) 3/10/2023 IV BOLUS 11
  • 12. 3. A new drug was given in a single iv dose of 200 mg to an 80-kg adult male patient. After 6 hrs, the plasma drug conc. of drug was 1.5 mg/100 mL of plasma. Assuming that the apparent VD is 10% of body weight, compute the total amount of drug in the body fluids after 6 hours. What is the half-life of this drug? 4. A drug has an elimination t 1/2 of 6 hours. If a single 200- mg dose is given to an adult male patient (68 kg) by IV bolus, what percent of the dose is lost in 24hrs? 3/10/2023 IV BOLUS 12
  • 13. 3/10/2023 IV Multiple dose 13 Multiple IV bolus dosing One compartment model
  • 14. Objectives • Discuss drug accumulation after repeated dose administration • Explain loading dose, maintenance dose, and dosing interval • Calculate appropriate multiple dose regimen – to achieve desired Cpmin/Cpmax values 3/10/2023 IV Multiple dose 14
  • 15. 3/10/2023 IV Multiple dose 15 1. Introduction • Most drugs are given as MDR –MDR → prolonged therapeutic activity • In designing a MDR, –the target Cp must be related to the therapeutic response –CP must be maintained within the TW –p’k parameters are first obtained from single-dose studies • Two main parameters - adjusted in MDR 1. Dose (Do) 2. Dosing interval (T)
  • 16. 3/10/2023 IV Multiple dose 16 1. Introduction… • Superimposition is assumed ►early doses don’t affect the p’k of subsequent doses ►CP after the 2nd , 3rd or nth dose will overlay/superimpose the CP attained after the (n–1)th dose ►Allows prediction of CP after multiple doses from a dose Accumulation • Subsequent doses given before drug from previous dose(s) eliminated
  • 17. Accumulation... • Example: Rx: 100 mg dose qid (4mg/ml every 6h) - (Literature data t1/2 = 6 hr and V = 25 L) 3/10/2023 IV Multiple dose 17
  • 18. 2. Accumulation... • As a table 3/10/2023 IV Multiple dose 18 Start End Cp lost 4 --> 2 mg/L 2 mg/L 6 --> 3 mg/L 3 mg/L 7 --> 3.5 mg/L 3.5 mg/L 7.5 --> 3.75mg/L 3.75mg/L ... --> ... ... 8 --> 4mg/L 4mg/L
  • 19. Drug accumulation... Development of a General Equation • At start of the first dose Cp1= Cp1 0 • At the end of the first dosing interval,  Cp1 = Cp1 0*e-k* • At the start of the second interval Cp2 0 = Cp1 0 + Cp1 = Cp1 0 + Cp1 0*e-k* • At the end of the 2nd dosing interval,  Cp2 = Cp1 0*e-k* +Cp1 0*(e-k*)2 • At the start of the 3rd interval Cp3 = Cp1 0 + Cp1 0*e-k* +Cp1 0*(e-k*)2 3/10/2023 IV Multiple dose 19
  • 20. Drug accumulation Geometric Series – Start of Interval, n • Cpn 0 = Cp1 0 + Cp1 0 • R + Cp1 0 •R2 +...+ Cp1 0 •Rn-1 – End of Interval, n » Cpn T = Cp1 0 • R + Cp1 0 •R2 + Cp1 0 • R 3+ ...+ Cp1 0 •Rn Sum of Geometric Series At Start of Interval n (Cmax) – Cpn 0 = Cp1 0[(1-Rn)/(1-R)] = D/VD[(1-e-nkT)/(1-e-kT)] – At the End of Interval n (Cmin) – Cpn T = Cp1 0[(1-Rn)/(1-R)].R = D/VD[(1-e-nkT)/(1-e-kT)]. e-kT 3/10/2023 IV Multiple dose 20
  • 21. 3/10/2023 IV Multiple dose 21 Steady state/plateau • Peak or max. conc. at steady state Cmax,ss = Cp o * 1 = Do x 1 (1-e-k) Vd (1-e-k) • Minimum or trough conc. at steady state Cmin,ss = Cp o * e-k = Do x e-k (1-e-k) Vd (1-e-k) • Cmax,ss & Cmax,ss must be with in the TW • 4 to 5 t1/2 to reach steady state
  • 22. Drug accumulation • Example – Rx: 100 mg q6h; Assume the drug has t1/2 = 4 hr; k=0.17h-1; V = 10L; R = e-0.17x6 = 0.35 • Question: What are Cmax and Cmin – Cmax = Cp1 0 /(1-R) = Dose/v.(1-R)= 100/10.(1-0.35)=15.5mg/L and – CpT ∞ = Cmin=Dose.R/v.(1-R)=15.5mg/L x 0.35=5mg/L 3/10/2023 IV Multiple dose 22
  • 23. 3/10/2023 IV Multiple dose 23 Loading and maintenance doses • Loading dose/priming –The required Cp is quickly achieved –DL = DM/(1-e-k)  DL→ loading dose  Dm→ maintenance dose • Example Approach to Cmax – Loading Dose = Cmax •V = 15.5 x 10 = 155mg – Dosing Regimen: 155 mg IV loading dose followed by 100 mg q6h
  • 24. Loading and maintenance doses • E.g., Rx: a physician wants to achieve plasma drug level of Cmax=35 mg/L; Cmin=10mg/L after adm of an antibiotics as MRD; (assume the Vd and k of drug are 25 L; and k= 0.15h-1, respectively). – Question: Calculate Dosage Regimen • Cmax/Cmin = 1/R • R=10/35 = 0.2857= e-k, • =8.35 – Using a dosing interval of 8h, R = e-k= e-8´0.15 = 0.3012 – Cmax = Do V• (1-R) – Dose = Cmax •V• (1-R) = 35 ´ 25 ´ (1- 0.3012) = 611 mg 3/10/2023 IV Multiple dose 24
  • 25. Loading and maintenance doses • The Dosing Regimen – Loading Dose = Cmax • V = 35 x 25 = 875 mg – Loading Dose: 875 – Maintenance Dose: 600 mg q8h – Rx = 600mg TID, first adm a loading dose of 875mg 3/10/2023 IV Multiple dose 25
  • 26. Average steady state blood levels • Where – Do = maintenance dose, – F = fraction of dose absorbed, –  = dosing interval – t1/2 = half life – 1.44 = reciprocal of 0.693 10 March 2023 MDR 26
  • 27. Designing dosage regimen 10 March 2023 MDR 27 • Example 1: The elimination half-life of an antibiotic is 3 hours and the apparent volume of distribution is 20% of body weight. The therapeutic window for this drug is from 2 to 10 µg/mL. Adverse toxicity is often observed at drug concentrations above 15 µg/mL. The drug will be given by multiple IV bolus injections. – a. Calculate the dose for an adult male patient (68 years old, 82 kg) with normal renal function to be given every 8 hours. – b. Calculate the C ∞ av value.
  • 28. Designing dosage regimen 10 March 2023 MDR 28 • A • B
  • 29. Designing dosage regimen 10 March 2023 MDR 29 • 2. Gentamicin has an average elimination half-life of approximately 2 hours and an apparent volume of distribution of 20% of body weight. It is necessary to give gentamicin, 1 mg/kg every 8 hours by multiple IV injections, to a 50-kg woman with normal renal function. • Calculate (a) Cmax, and (b) C ∞ av.
  • 30. Designing dosage regimen 10 March 2023 MDR 30 b.
  • 31. Designing dosage regimen 10 March 2023 MDR 31 • Example 3: A patient receives 1000 mg every 6 hours by repetitive IV injection of an antibiotic with an elimination half-life of 3 hours. Assume the drug is distributed according to a one-compartment model and the volume of distribution is 20 L. – Find the average amount of drug in the body.
  • 32. Designing dosage regimen 10 March 2023 MDR 32 • Example 4. Patient C.S. is a 35-year-old male weighing 76.6 kg. The patient is to be given multiple IV bolus injections of an antibiotic every 6 hrs. The effective conc. of this drug is 15 µg/mL. After the patient is given a single IV dose, the elimination half-life for the drug is determined to be 3.0 hr and the VD is 196 mL/kg. Determine a multiple IV dose regimen for this drug.
  • 33. Designing dosage regimen 10 March 2023 MDR 33
  • 34. IV INFUSION ONE COMPARTMENT OPEN MODEL 3/10/2023 IV INFUSION 34
  • 35. 3/10/2023 IV INFUSION 35 Introduction • Given slowly at a constant or zero-order rate • maintains an effective constant plasma [drug] – For drugs with a narrow TW • allows precise control of plasma [drug] to fit the individual needs of the patient • [Drug] is constant after a plateau or steady-state
  • 36. 3/10/2023 IV INFUSION 36 CP - t relationship At steady state: • Rate at which the drug is leaving the body is equal to the rate entering the body • Infusion rate = elimination rate • Rate of drug input = rate of drug output • zero-order input and first-order output • No net change in the Cp dCp/dt = 0
  • 37. 3/10/2023 IV INFUSION 37 CP - t relationship…. • Change in the amount of drug in the body at any time = – rate of input minus the rate of output – (dDB/dt) = R - kDB …………1 R = infusion rate→ Dose/duration of infusion DB = amount of drug in the body K = 1st order elimination rate constant • Integration above eq. and substitution of DB =C pVD gives – Cp = R (1-e-kt)………………2 kVD
  • 38. 3/10/2023 IV INFUSION 38 Steady state Concentration (CSS) • no net change in the amount of drug in the body Cp = (R/kVD)(1-e-kt) • Theoretical Css is at t = ∞ • At t = ∞, e–kt approaches zero Css= R/kVD = R/Cl • CSS depends on R, k & VD
  • 39. 3/10/2023 IV INFUSION 39 Time to reach CSS • Drug elimination is exponential (1st order) – CP becomes asymptotic to the theoretical CSS • Mathematically, the time to reach true steady-state drug concentration, CSS, would take an infinite time • The time for the CP to reach more than 95% of the CSS is often taken as time for CSS • About 4 to 5 t1/2 • = Time to reach desired therapeutic conc.
  • 40. 3/10/2023 IV INFUSION 40 Time to reach CSS…… Number of t 1/2 to reach a fraction of C SS Percent of CSS reached Number of t1/2 90 3.32 95 4.32 99 6.65
  • 41. 3/10/2023 IV INFUSION 41 Time to reach CSS…… Example: no of t1/2 to reach 99% CSS • Css= R/kVD Cp = (R/kVD)(1-e-kt) 0.99 Css = Css (1-e-kt) 0.01 = e-kt t99%SS= ln(0.01)/-k = 4.61/k = (4.61/0.693) t1/2= 6.65t1/2 • not dependent on the rate of infusion (an increase infusion rate will not shorten the time to reach steady state • Depends on the elimination rate constant or t1/2
  • 42. 3/10/2023 IV INFUSION 42 Cp after infusion period • If infusion stops at steady state or before steady, CP declines according to first-order kinetics • Stopped after steady state Ct =Csse-kt t → time after the infusion • Similar to IV bolus, Co= Css
  • 43. 3/10/2023 IV INFUSION 43 Loading Dose (DL) Plus IV Infusion • initial bolus dose used to obtain desired conc. as rapidly as possible – [drug] after an IV bolus dose C1 = Co. e-kt =(DL/VD)e-kt – [drug] by infusion, C2 = (R/VDK) (1-e-kt) • If DL & infusion is started at the same, Cp at t hours = C1 + C2 – Cp =(DL/VD) e-kt + (R/VD K) (1-e-kt) – Cp = (DL/VD) e-kt + (R/VD K - R/VD K e-kt) – Cp = R/VD K + (DL/VDe-kt - R/VD K e-kt) • Let DL equal the amount of drug at SS, DL = Css VD = R/K
  • 44. DL Plus IV Infusion… • Cp= R/VD K + (DL/VDe-kt - R/VD K e-kt) • Substituting D L = R/k in above eq. makes the expression in parentheses cancel out. • Equation, therefore, is the same expression for CSS or steady-state plasma concentration: • Cp= R/VD K • Css = R/VD K 3/10/2023 IV INFUSION 44
  • 45. Examples 1. A physician wants to administer an anesthetic agent at a rate of 2 mg/hr by IV infusion. The elimination rate constant is 0.1 hr– 1, and the volume of distribution is 10 L. What loading dose should be recommended if the doctor wants the drug level to reach 2µg/mL immediately? 2. What is the concentration of a drug 6 hours after administration of a loading dose of 10 mg and simultaneous infusion at 2 mg/hr (the drug has a t 1/2 of 3 hr and a volume of distribution of 10 L)? 3/10/2023 IV INFUSION 45
  • 46. 3. . A female patient (35 years old, 65 kg) with normal renal function is to be given a drug by IV infusion. According to the literature, the elimination half-life of this drug is 7 hours and the apparent V D is 23.1% of body weight. The pharmacokinetics of this drug assumes a first-order process. The desired steady-state plasma level for this antibiotic is 10 µg/mL. • a. Assuming no loading dose, how long after the start of the IV infusion would it take to reach 95% of the C SS? • b. What is the proper loading dose for this antibiotic? • c. What is the proper infusion rate for this drug? • d. What is the total body clearance? • e. If the total body clearance declined 50% due to partial renal failure, what new infusion rate would you recommend to maintain the desired steady-state plasma level of 10 µg/mL? • 3/10/2023 IV BOLUS 46
  • 48. 3/10/2023 p'k of extravascular dose 48 Pharmacokinetics of extravascular dose One compartment model
  • 49. 1. Introduction Extravascular • Not IV • Involve an Absorption Step including Oral, IM, SC, etc. • Absorption Defined by Rate and Extent 3/10/2023 p'k of extravascular dose 49
  • 50. 3/10/2023 p'k of extravascular dose 50 Introduction... Oral route (oral doses)- Most commonly used route of admn. • The rate of change in the amount of drug in the body, dDB/dt, is the function of absorption and elimination rate. • dDB/dt = dDGI/dt - dDE/dt
  • 51. 3/10/2023 p'k of extravascular dose 51 EV single dose equation A. zero-order absorption Cp = ko/(kVD)(1-e-kt) B. 1st- order absorption CP = FKaDo[e-kt - e-kat] VD(Ka-k) F Dose Dose and DF parameters Ka Kel Drug and Patient parameters V
  • 52. 3/10/2023 p'k of extravascular dose 52 Pharmacokinetic Parameters 1. tmax ,Time for maximum CP • tmax = 1 ln Ka Ka-K K • independent of Do • depend on ka and k • Cmax is CP at tmax K Ka K) (Ka . t log 303 2 max  
  • 53. 3/10/2023 p'k of extravascular dose 53 2. determination of K • Determined from the elimination phase of the Cp–time curve CP = FKaDo[e-kt - e-kat] VD(Ka-k) • Assuming k a >> k in above Equation, the value for the second exponential will become insignificantly small with time (ie, e –k a t ≈ 0) CP = FKaDo e-kt VD(Ka-k) CP = Ae-kt; A = fDKa/[VD(Ka-K)]
  • 54. determination of K... • CP = Ae-kt; • This equation represents first-order drug elimination, • Plot logCp vs t – slope = -k/2.3 – Intercept A – Similar to IV bolus dose 3/10/2023 p'k of extravascular dose 54
  • 55. 3/10/2023 p'k of extravascular dose 55 3. Determination of Ka- Method of residuals • Back Extrapolate the elimination phase curve to t=0 – Curve AC is obtained • Take ≥3 points on the upper part of AC – eg, x'1, x'2, x'3, ... • Drop vertically to obtain corresponding points on the curve – eg, x1, x2, x3, . . .
  • 56. 3/10/2023 p'k of extravascular dose 56 Ka-Method of residuals….. • Plot the values of the d/ces at the corresponding time points – x'1-x1, x'2-x2, x'3-x3, ... • A straight line will be obtained slope =-ka/2.3 • Equation of the residual line C’ = [fDKa/(VD(ka-K))]e-kat C’ = x‘i-xi
  • 57. 3/10/2023 p'k of extravascular dose 57 4. Lag time-Method of residuals • Time b/n administration and start of absorption – Enteric coating tablets – Gastric emptying – Dissolution of capsule shell The lag time t0 is subtracted from each time point CP = FKaDo [e-k(t-to) - e-ka(t-to)] VD(Ka-k) 5. Elimination half life t1/2= 0.693/k
  • 58. 58 Effect of ka on Cmax, tmax, & AUC • Increasing the absorption rate constant (Ka) results in: – Shorter tmax – Higher Cmax – Unchanged AUC Changing Ka ( K unchanged)
  • 59. 59 Effect of K on tmax, Cmax, and AUC • Increasing the elimination rate constant (K) results in: – Shorter tmax – Lower Cmax – Lower AUC Changing K ( Ka unchanged)
  • 60. 60 Effect F on tmax, Cmax, and AUC 0 50 100 150 200 250 300 0 20 40 60 80 100 time Concentration F = 1 F = 0.5 F = 0.25  Increasing the bioavailability results in:  Unchanged tmax  Higher Cmax  Higher AUC
  • 61. Example A single oral dose (600 mg) of an antibiotic (90% bioavailable) was given to an adult male patient (43 years, 72 kg). From the literature, the drug has ka = 1.0 hr-1, kel = 0.15 hr-1, and V = 30 liter. calculate t max, C max, and t 1/2 for the drug in this patient.. 3/10/2023 p'k of extravascular dose 61
  • 62. 3/10/2023 p'k of extravascular dose 62 MDR-extravascular
  • 63. Multiple-Oral-Dose Regimen • Cp at any time during an oral or EV MDR, assuming a one-compartment model and constant doses and dose interval, can be determined as follows: – where • n = number of doses, • T= dosage interval, • F = fraction of dose absorbed, and • t = time after administration of n doses 3/10/2023 p'k of extravascular dose 63
  • 64. 3/10/2023 p'k of extravascular dose 64 Cp-time
  • 65. 3/10/2023 p'k of extravascular dose 65 C∞ max, C∞ min, C∞ av tp –time for peak conc. at steady state • C∞ av = FDo/VdK
  • 66. 3/10/2023 p'k of extravascular dose 66 Loading dose, DL • To reduce the onset time of the the time it takes to achieve the MEC • DL/DM = 1/(1-e-kaT)(1-e-kT) • Practically, for most drugs Ka>>>K • DL/DM = 1/(1-e-kT) DL = DM/(1-e-kT)
  • 67. Example • An adult male patient (46 yrs old, 81 kg) was given orally 250 mg of TTC HCl TID for 2 weeks. From the literature, TTC is about 75% bioavailable and has Vd of 1.5 L/kg. k is about 0.07 hr– 1 & Ka is 0.9 hr– 1. From this information, calculate (a) plasma drug concentration C p at 4 hours after the 7th dose, Here, n=7, t=4, Ꞇ=8 3/10/2023 p'k of extravascular dose 67
  • 68. (b) maximum plasma drug concentration at steady-state C ∞ max, 3/10/2023 p'k of extravascular dose 68
  • 69. (c) minimum plasma drug concentration at steady-state C ∞ min, and (d) average plasma drug concentration at steady-state C ∞ av. 3/10/2023 p'k of extravascular dose 69
  • 70. 10 March 2023 MDR 70 • Example 2. A physician wants to give theophylline to a young male asthmatic patient (age 29, 80 kg). According to the literature, the drug has k of 5 hrs & VD equal to 50% of body weight. The plasma level of theophylline required to provide adequate airway ventilation is approximately 10 µg/mL. – a. The physician wants the patient to take medication every 6 hours around the clock. What dose of theophylline would you recommend (assume theophylline is 100% bioavailable)? – b. If you were to find that theophylline is available to you only in 225-mg capsules, what dosage regimen would you recommend?
  • 71. 10 March 2023 MDR 71
  • 73. Dosage regimen 10 March 2023 73 Dosage Regimen – the manner in which the drug is taken. – Some are taken as single dose, however, most drugs are taken on a repetitive bases – For successful therapy, design of an optimal multiple dosage regimen (MDR) is necessary. • MDR:- is the manner in which the drug is administered in suitable doses by suitable route, with sufficient frequency that insures maintenance of Cp within TI for entire period of therapy.
  • 74. Approaches to Design of Dosage Regimen 74 The various approaches employed in designing a dosage regimen are – 1. Empirical Dosage Regimen 2. Population Averages Dosage Regimen (a) Fixed model (b) Adaptive model 3. Individualized Dosage Regimen » based on the phks of drug in the individual patient.
  • 75. 1. Empirical Dosage Regimen 75 Designed by the physician based on – Empirical clinical data, – Personal experience and – Clinical observations. • In many cases, the physician selects a DR for the patient without using any ph’k variables. • This approach is, however, not very accurate.
  • 76. 2. Population Averages Dosage Regimens 76 DR based on Population Averages– • Is the most often used approach. • is based on one of the two models a) The fixed model – Based on population average ph’k parameters. – This parameters are used directly to calculate a DR for the patient. • Ph’k parameters such as ka, F, VD, & k, are assumed to remain constant. • Drug is assumed to follow the phk of a one-compartment model. • When a MDR is designed, multiple-dosage equations based on the principle of superposition are used to evaluate the dose.
  • 77. b) The adaptive model 77 The adaptive model is Based on  Population average ph’k parameters of the drug as well as  Patient variables such as weight, age, sex, body surface area and known patient pathophysiology such as renal disease. • Calculation of the DR takes into consideration – any changing pathophysiology of the patient & attempts to adapt or modify the DR according to the needs of the patient.
  • 78. Fixed model: Designing MDR 78 Irrespective of the route of adm. & complexity of ph’k equations, the two major parameters that can be adjusted in developing a DR are 1. The dose size 2. The dosing frequency Both parameters govern the amount of drug in the body at any given time.
  • 79. Fixed Model: Dose size 79 The magnitude of both therapeutic and toxic responses depends upon dose size. • Greater the dose size, greater the fluctuations between Css,max & Css,min during each dosing interval & greater the chances of toxicity (Fig. below). • For drugs administered chronically, dose size calculation is based on average Css & is computed from equation:
  • 80. Fixed Model: Dose size 80 Fig: influence of dose size on CpVs t after oral adm of a drug at fixed intervals of time.
  • 81. Fixed Model: Dose size Determination of Dose: Examples 81 According to literature, the t1/2 of tobramycin was reported to be 2.15 hrs & the VD was reported to be 33.5% of body weight. What is the dose for an 80-kg pt if Css level of 2.5 g/mL is desired? Assume that the drug is given by IV bolus injection TID. • Solution Assuming the drug is 100% BA as a result of IV injection, • The dose should be 173 mg every 8 hours.
  • 82. Fixed Model: Dosing Frequency 82 • The dose interval (inverse of dosing frequency) is calculated on the basis of half-life of the drug. • If the interval is increased and the dose is unchanged, Cmax, Cmin and Cav decrease but the ratio Cmax/Cmin increases. • Opposite is observed when dosing interval is reduced or dosing frequency increased. – It also results in greater drug accumulation in the body and toxicity (see Fig.).
  • 83. Fixed Model: Dosing Frequency 83 Fig: influence of dosing frequency on CpVs t profile after oral adm of a drug at fixed dose of a drug
  • 84. Fixed Model: Dosing Frequency 84 • A proper balance b/n both dose size and dosing frequency is often desired to attain steady-state conc. with minimum fluctuations and to ensure therapeutic efficacy & safety. – The same cannot be obtained by giving larger doses less frequently. – However, administering smaller doses more frequently results in smaller fluctuations
  • 85. Fixed Model: Dosing Frequency… 85 Generally speaking, every subsequent dose should be administered at an interval equal to half-life of the drug. A rule of thumb is that – • For drugs with wide TI such as penicillin, – Larger doses may be administered at relatively longer intervals (˃t1/2 of drug) without any toxicity problem • For drugs with narrow TI such as digoxin, – Small doses at frequent intervals (usually ˂ t1/2) is better to obtain a profile with least fluctuations (similar to constant rate infusion or controlled-release system).
  • 86. Fixed Model: Dosing Frequency Determination of Frequency Example 86 • For example, – Dm of digoxin is 0.25 mg/day & its t1/2 is 1.7 days. – Dm of penicillin G is 250 mg QID, while its t1/2 is 0.75 hr. – Penicillin is given at  = 8x t1/2 , whereas digoxin is given at  = 0.59x t1/2 0.59. – The toxic Cp of penicillin G is over 100x ˃ its effective Cp, – The toxic Cp of digoxin is only 1.5x ˃ its effective. • Therefore, – a drug with a large TI can be given in large doses and at relatively long dosing intervals.
  • 87. Fixed Model: Dosing Frequency Determination of Frequency Example 87 The size of a drug dose is often related to the frequency of drug administration. • The more frequently a drug is administered, the smaller the dose must be to obtain the same C∞ av. • Thus, a dose of 250 mg every 3 hours could be changed to 500 mg every 6 hours without affecting the C∞ av of the drug. – However, as dosing intervals , the size of the dose required to maintain the C∞ av gets larger. – When an excessively long dosing interval is chosen, the large dose may result in peak plasma levels that are above toxic drug conc, even though C∞ av will remain the same.
  • 88. Fixed Model: Determination of Both Dose and Dosage Interval 88 • Both Do &  should be considered in the DR calculations. • Ideally, the calculated DR should maintain the serum drug conc between C∞ max and C∞ min. • For IV MDR the ratio of C ∞ max/C ∞ min may be expressed by • Which can be simplified to
  • 89. Fixed Model: Determination of Both Dose and Dosage Interval 89 Practice Problem • The t1/2 of an antibiotic is 3 hrs with Vd of 20% of body Wt. The usual therapeutic range for this antibiotic is between 5 & 15g/mL. Calculate a DR (multiple IV doses) that will just maintain the serum drug conc b/n 5 & 15g/mL. Solution • From the above Equation, determine the maximum possible dosage interval . Take the natural logarithm (ln) on both size of the equation
  • 90. Fixed Model: Determination of Both Dose and Dosage Interval 90 By calculation, the dose of this antibiotic should be 2 mg/kg every 4.76 hours to maintain the serum drug concentration between 5 and 15  g/mL.